Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Gaël S. Roth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5822-4320; OpenAlex author ID A5017079089. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 9

  1. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Co-author DOI 10.1016/j.dld.2026.10.006↗
  2. Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10436-4↗
  3. Targeted photodynamic therapy for pancreatic cancer: recent innovations from fundamentals to in vivo and clinical applications (2020-2025). Co-author DOI 10.1039/d5cc05629b↗
  4. Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study). Co-author DOI 10.1016/j.esmogo.2025.100142↗
  5. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  6. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  7. Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort. Co-author DOI 10.3390/cancers14215413↗
  8. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Co-author DOI 10.3390/cancers13112797↗
  9. Lysine methylation signaling in pancreatic cancer. Co-author DOI 10.1097/cco.0000000000000421↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nicolas Williet · 7 shared papers, 2021–2026 · strength 1.19
  2. Olivier Bouché · 5 shared papers, 2022–2026 · strength 0.95
  3. Jean‐Baptiste Bachet · 3 shared papers, 2024–2026 · strength 0.60
  4. Camille Evrard · 3 shared papers, 2022–2026 · strength 0.55
  5. Cindy Neuzillet · 2 shared papers, 2024–2026 · strength 0.40
  6. Mathias Brügel · 2 shared papers, 2022–2025 · strength 0.35
  7. David Tougeron · 2 shared papers, 2022–2025 · strength 0.35
  8. Christelle d’Engremont · 2 shared papers, 2022–2026 · strength 0.31
  9. Anthony Turpin · 2 shared papers, 2022–2026 · strength 0.31
  10. Christelle de la Fouchardière · 2 shared papers, 2022–2024 · strength 0.27
  11. Marie Müller · 1 shared paper, 2025 · strength 0.25
  12. Déwi Vernerey · 1 shared paper, 2026 · strength 0.24
  13. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  14. Victoire Cardot‐Ruffino · 1 shared paper, 2026 · strength 0.24
  15. Brice Chanez · 1 shared paper, 2026 · strength 0.24
  16. Marc Hilmi · 1 shared paper, 2026 · strength 0.24
  17. Souleymane Sarr · 1 shared paper, 2026 · strength 0.21
  18. Nadira Delhem · 1 shared paper, 2026 · strength 0.21
  19. Anne‐Laure Bulin · 1 shared paper, 2026 · strength 0.21
  20. Hélène Burckel · 1 shared paper, 2026 · strength 0.21
  21. Vincent Sol · 1 shared paper, 2026 · strength 0.21
  22. Nicolas Jonckheere · 1 shared paper, 2026 · strength 0.21
  23. Mircea Chirica · 1 shared paper, 2026 · strength 0.20
  24. Pauline Parent · 1 shared paper, 2026 · strength 0.20
  25. Jean‐Frédéric Blanc · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.